Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -29.57% is 253% below its 5-year average of -8.39%, around the middle of its 5-year range (-60.32%–21.12%).
26.88% above its 12-month average of -40.44%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
RETURN ON ASSETS (ROA)
-29.57%
RETURN ON ASSETS (ROA) AVG TTM
-40.44%
RETURN ON ASSETS (ROA) AVG 3Y
-13.88%
RETURN ON ASSETS (ROA) AVG 5Y
-8.39%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+26.88%
CURRENT VS 3Y AVG
-112.96%
CURRENT VS 5Y AVG
-252.51%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+8.28%
vs the sector median at left
YD Bio Limited Ordinary Shares
Market Cap
$435.61M
Return on Assets (ROA)
-29.57%
TTM Avg
-40.44%
3Y Avg
-13.88%
5Y Avg
-8.39%
Market Cap
$438.07M
Return on Assets (ROA)
-83.42%
TTM Avg
-53.06%
3Y Avg
-45.42%
5Y Avg
-42.54%
Market Cap
$431.97M
Return on Assets (ROA)
-19.71%
TTM Avg
-24.50%
3Y Avg
-30.22%
5Y Avg
-31.88%
Market Cap
$439.55M
Return on Assets (ROA)
-0.01%
TTM Avg
-18.05%
3Y Avg
-43.07%
5Y Avg
-43.70%
Market Cap
$442.34M
Return on Assets (ROA)
-14.87%
TTM Avg
-20.11%
3Y Avg
-27.86%
5Y Avg
-25.84%
Market Cap
$426.51M
Return on Assets (ROA)
-86.35%
TTM Avg
-25.00%
3Y Avg
-21.41%
5Y Avg
-20.43%
Market Cap
$445.71M
Return on Assets (ROA)
-35.10%
TTM Avg
-26.63%
3Y Avg
-37.28%
5Y Avg
-39.51%
Market Cap
$424.10M
Return on Assets (ROA)
-3.84%
TTM Avg
-6.38%
3Y Avg
-6.57%
5Y Avg
-4.38%
Market Cap
$422.86M
Return on Assets (ROA)
-36.19%
TTM Avg
-33.16%
3Y Avg
-60.79%
5Y Avg
-52.41%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| YD Bio Limited Ordinary Shares (YDES) | $435.61M | -29.57% | -40.44% | -13.88% | -8.39% |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $438.07M | -83.42% | -53.06% | -45.42% | -42.54% |
| NeuroPace, Inc. (NPCE)vs › | $431.97M | -19.71% | -24.50% | -30.22% | -31.88% |
| Assembly Biosciences, Inc. (ASMB)vs › | $439.55M | -0.01% | -18.05% | -43.07% | -43.70% |
| Ovid Therapeutics Inc. (OVID)vs › | $442.34M | -14.87% | -20.11% | -27.86% | -25.84% |
| ARS Pharmaceuticals, Inc. (SPRY)vs › | $426.51M | -86.35% | -25.00% | -21.41% | -20.43% |
| Capricor Therapeutics, Inc. (CAPR)vs › | $445.71M | -35.10% | -26.63% | -37.28% | -39.51% |
| NeoGenomics, Inc. (NEO)vs › | $424.10M | -3.84% | -6.38% | -6.57% | -4.38% |
| Tectonic Therapeutic, Inc. (TECX)vs › | $422.86M | -36.19% | -33.16% | -60.79% | -52.41% |
| Tilray Brands, Inc. (TLRY)vs › | $422.72M | -6.40% | -54.29% | -36.81% | -26.71% |
ROA
-29.6%
ROE
-66.5%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -60.32% |
| 2024-12-31 | -20.56% |
| 2023-12-31 | 4.22% |
| 2022-12-31 | 21.12% |
| 2021-12-31 | 7.37% |
| 2020-12-31 | -2.16% |
